Bevacizumab
Copyright policy )Bevacizumab
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
- The University of Texas MD Anderson Cancer Center United States
Vascular Endothelial Growth Factor A, Clinical Trials as Topic, Antibodies, Monoclonal, Angiogenesis Inhibitors, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Bevacizumab, Treatment Outcome, Humans, Colorectal Neoplasms
Vascular Endothelial Growth Factor A, Clinical Trials as Topic, Antibodies, Monoclonal, Angiogenesis Inhibitors, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Bevacizumab, Treatment Outcome, Humans, Colorectal Neoplasms
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).81 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!